Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on developing treatments for neurodegenerative diseases, has appointed Abby Macnish Niven as its new Chief Financial Officer (CFO), effective immediately. CEO David Stamler expressed confidence in Ms Macnish Niven's broad experience and financial background to help advance the company's programs.
Ms Macnish Niven brings extensive experience in private wealth management from groups including ANZ, UBS, and Ord Minett. She also consults for various listed and unlisted companies in governance, finance, and corporate structure. She holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.
Ms Macnish Niven replaces Mr Phillip Hains, who served as CFO since December 2023. Mr Hains will continue as Company Secretary.
Positive
- Appointment of a new CFO with extensive financial experience
- New CFO has a background in private wealth management and corporate consulting
- Continuity in company leadership with the former CFO remaining as Company Secretary
Negative
- None.
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company’s Chief Financial Officer (CFO), effective today.
“We look forward to Abby’s contributions whose broad experience and financial background will help us advance our programs. I would also like to express my gratitude to Phillip and his team who supported us during a transition period,” said David Stamler, M.D., Chief Executive Officer of Alterity.
Ms Macnish Niven has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett. Ms Macnish Niven consults to a range of listed and unlisted companies in governance, finance and corporate structure. Ms Macnish Niven holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.
Ms Macnish Niven will replace Mr Phillip Hains, who supported Alterity as CFO from December 2023. Mr Hains continues as Company Secretary.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ
Who is the new CFO of Alterity Therapeutics (ATHE)?
What is Abby Macnish Niven's background before joining Alterity Therapeutics (ATHE)?
When did Abby Macnish Niven start as CFO of Alterity Therapeutics (ATHE)?
Who did Abby Macnish Niven replace as CFO at Alterity Therapeutics (ATHE)?
